Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 4,513 matching trials from the live ClinicalTrials.gov search.
Filters: Lexington, Kentucky Clear all
Completed Phase 3 Interventional Results available

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

NCT00891020
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
227
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

NCT00139841
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Bendamustine HCl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

NCT01499420
View directory record Official record
Conditions
Stable Atherothrombotic Disease
Interventions
CSL112 (reconstituted high density lipoprotein), Placebo
Biological
Lead sponsor
CSL Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Chula Vista, California • Jacksonville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

NCT02448641
View directory record Official record
Conditions
Chronic Ischemic Stroke
Interventions
SB623 Implant (2.5M), SB623 Implant (5.0M), Sham surgery
Biological · Procedure
Lead sponsor
SanBio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Carlsbad, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 20, 2026, 5:31 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cocaine and Pentoxifylline (BED IN 47)

NCT07086794
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Placebo, Cocaine (IV), Pentoxifylline
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

ClearVoice Sound-processing Strategy for AB HiRes 120 Cochlear Implant Users

NCT01066780
View directory record Official record
Conditions
Implant
Interventions
ClearVoice
Device
Lead sponsor
Advanced Bionics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Los Angeles, California • Urbana, Illinois • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00057746
View directory record Official record
Conditions
Lung Cancer
Interventions
Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
217
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Adolescent Vaccination in Appalachian Kentucky

NCT01838161
View directory record Official record
Conditions
Adolescent Immunization
Interventions
Part II, Part III, Part I
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
11 Years to 70 Years
Enrollment
597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 20, 2026, 5:31 AM EDT
Active, not recruiting Phase 1 Interventional

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

NCT03528642
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Interventions
Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide
Other · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed No phase listed Observational

Ocriplasmin Research to Better Inform Treatment (ORBIT)

NCT02079883
View directory record Official record
Conditions
Symptomatic Vitreomacular Adhesion
Interventions
Not listed
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 92 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

NCT00063141
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, Irinotecan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
116
States / cities
Tucson, Arizona • Pine Bluff, Arkansas • Bakersfield, California + 104 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2010 · Synced Oct 20, 2026, 5:31 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Ketamine and Epigenetic Aging

NCT05294835
View directory record Official record
Conditions
Depression, Post Traumatic Stress Disorder
Interventions
Ketamine
Drug
Lead sponsor
TruDiagnostic
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

PREGNANT Short Cervix Trial

NCT00615550
View directory record Official record
Conditions
Preterm Delivery, Short Cervix, Short Uterine Cervical Length
Interventions
progesterone, placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

NCT00002368
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Lamivudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
53
States / cities
Montgomery, Alabama • Los Angeles, California • Palo Alto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

NCT02289950
View directory record Official record
Conditions
Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions
Farletuzumab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
35
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725
View directory record Official record
Conditions
Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions
Odiparcil, Warfarin, Coumadin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 20, 2026, 5:31 AM EDT
Completed No phase listed Observational

Study of Procoagulation Markers in Stroke Patients

NCT01811550
View directory record Official record
Conditions
Stroke, Hyperglycemia, Procoagulation Markers
Interventions
Glycemic Control
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 20, 2026, 5:31 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder

NCT01467713
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ramelteon SL, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
138
States / cities
Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

Aripiprazole to Reduce Cocaine Relapse

NCT00276874
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Aripiprazole, Placebos
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 20, 2026, 5:31 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Rapid Point-of-Care Salivary Diagnostic for Periodontal Health

NCT02403297
View directory record Official record
Conditions
Gingivitis, Periodontal Disease
Interventions
Quik Check PD
Device
Lead sponsor
Innovative Diagnostics Inc
Industry
Eligibility
18 Years to 95 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 20, 2026, 5:31 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension for Phase 3 Clinical Trials of Simufilam

NCT05575076
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
51 Years to 89 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Breast Cancer Recurrence Risk Counseling

NCT03339518
View directory record Official record
Conditions
Breast Cancer Female
Interventions
BRIM3 educational intervention, Wait List
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Lexington, Kentucky • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT06034743
View directory record Official record
Conditions
Uncontrolled Hypertension, Resistant Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Saraland, Alabama • Scottsdale, Arizona • Sun City West, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

NCT01438710
View directory record Official record
Conditions
Renal Failure, Tremors
Interventions
Prograf, LCP-Tacro
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 20, 2026, 5:31 AM EDT